Skye Bioscience Inc
NASDAQ:SKYE
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1.44
18
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one SKYE stock under the Base Case scenario is 2.35 USD. Compared to the current market price of 5.39 USD, Skye Bioscience Inc is Overvalued by 56%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Skye Bioscience Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for SKYE cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Skye Bioscience Inc
Balance Sheet Decomposition
Skye Bioscience Inc
Current Assets | 87m |
Cash & Short-Term Investments | 76.3m |
Receivables | 20 |
Other Current Assets | 10.7m |
Non-Current Assets | 257.1k |
PP&E | 248.8k |
Other Non-Current Assets | 8.3k |
Current Liabilities | 14.3m |
Accounts Payable | 1.1m |
Accrued Liabilities | 2.1m |
Short-Term Debt | 4.9m |
Other Current Liabilities | 6.2m |
Non-Current Liabilities | 129.9k |
Other Non-Current Liabilities | 129.9k |
Earnings Waterfall
Skye Bioscience Inc
Revenue
|
0
USD
|
Operating Expenses
|
-43.3m
USD
|
Operating Income
|
-43.3m
USD
|
Other Expenses
|
1.1m
USD
|
Net Income
|
-42.3m
USD
|
Free Cash Flow Analysis
Skye Bioscience Inc
USD | |
Free Cash Flow | USD |
SKYE Profitability Score
Profitability Due Diligence
Skye Bioscience Inc's profitability score is 41/100. The higher the profitability score, the more profitable the company is.
Score
Skye Bioscience Inc's profitability score is 41/100. The higher the profitability score, the more profitable the company is.
SKYE Solvency Score
Solvency Due Diligence
Skye Bioscience Inc's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
Skye Bioscience Inc's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SKYE Price Targets Summary
Skye Bioscience Inc
According to Wall Street analysts, the average 1-year price target for SKYE is 18.36 USD with a low forecast of 14.14 USD and a high forecast of 22.05 USD.
Dividends
Current shareholder yield for SKYE is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
SKYE Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Skye Bioscience, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of cannabinoid-based therapeutics. The company is headquartered in San Diego, California and currently employs 9 full-time employees. The company went IPO on 2014-02-24. The Company’s products programs include THCVHS and CBDVHS. The firm's lead candidate, THCVHS, is a prodrug of tetrahydrocannabinol (THC), is a topical formulation under development for the treatment of glaucoma and ocular hypertension (OHT). The company chemically modifies THC to create a unique synthetic molecule with the intent to realize the known positive effects of THC. Its molecule enables enhanced local delivery in the eye, reduced systemic side effects, and the potential for neuroprotection for the treatment of ocular diseases. CBDVHS is a proprietary analog of cannabidiol (CBD) that has demonstrated biological activity that is both pharmacologically and therapeutically distinct from CBD in various preclinical models.
Contact
IPO
Employees
Officers
The intrinsic value of one SKYE stock under the Base Case scenario is 2.35 USD.
Compared to the current market price of 5.39 USD, Skye Bioscience Inc is Overvalued by 56%.